Anandamide effects on 5-HT3 receptors in vivo

被引:23
|
作者
Racz, Ildiko
Bilkei-Gorzo, Andras
Markert, Astrid
Stamer, Friederike
Goethert, Manfred [2 ]
Zimmer, Andreas [1 ]
机构
[1] Univ Bonn, Life & Brain Ctr, Inst Mol Psychiat, D-53105 Bonn, Germany
[2] Univ Bonn, Inst Pharmacol, D-53105 Bonn, Germany
关键词
Cannabinoid receptors; 5-HT3; receptor; Anandamide; Delta(9)-tetrahydrocannabinol;
D O I
10.1016/j.ejphar.2008.08.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Studies in knockout mouse strains have shown that some cannabimimetic effects persist in animals lacking cannabinoid CB1 and CB2 receptors. These residual effects are thought to result, in part, from a cannabinoid-modulation of ion channels. This study investigates the role of 5-HT3 receptors as a potential in vivo target for cannabinoids. Mice deficient in CB1 and CB2 receptors were treated with Delta(9)-tetrahydrocannabinol and anandamide, in the presence of the 5-HT3 antagonist ondansetron. We show that the cannabinoid receptor-independent anandamide analgesia, but not catalepsy, is completely blocked by ondansetron. Thus, 5-HT3 receptors seem to be involved in cannabinoid analgesia. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:98 / 101
页数:4
相关论文
共 50 条
  • [21] Influence of sodium substitutes on 5-HT-mediated effects at mouse 5-HT3 receptors
    Barann, M
    Schmidt, K
    Göthert, M
    Urban, BW
    Bönisch, H
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 142 (03) : 501 - 508
  • [22] Influence of sodium substitutes on 5-HT-mediated effects at mouse 5-HT3 receptors
    Barann, M.
    Schmidt, K.
    Goethert, M.
    Urban, B. W.
    Boenisch, H.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 137 - 137
  • [23] Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors
    Cubeddu, LX
    Bönisch, H
    Göthert, M
    Molderings, G
    Racké, K
    Ramadori, G
    Miller, KJ
    Schwörer, H
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 361 (01) : 85 - 91
  • [24] Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors
    L.X. Cubeddu
    H. Bönisch
    M. Göthert
    G. Molderings
    K. Racké
    G. Ramadori
    K.J. Miller
    H. Schwörer
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361 : 85 - 91
  • [25] Interaction of S 21007 with 5-HT3 receptors. In vitro and in vivo characterization
    Delagrange, P
    Emerit, MB
    Merahi, N
    Abraham, C
    Morain, P
    Rault, S
    Renard, P
    Pfeiffer, B
    GuardiolaLamaitre, B
    Hamon, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 316 (2-3) : 195 - 203
  • [26] 5-HT activates vagal afferent cell bodies in vivo:: Role of 5-HT2 and 5-HT3 receptors
    Lacolley, P.
    Owen, J. R.
    Sandock, K.
    Lewis, T. H. J.
    Bates, J. N.
    Robertson, T. P.
    Lewis, S. J.
    NEUROSCIENCE, 2006, 143 (01) : 273 - 287
  • [27] Muscle relaxants and 5-HT3 receptors -: Response
    Yang, J
    ANESTHESIA AND ANALGESIA, 2000, 91 (04): : 1039 - 1039
  • [28] 5-HT3 RECEPTORS - PHARMACOLOGICAL AND THERAPEUTIC ASPECTS
    GYERMEK, L
    JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (09): : 845 - 855
  • [29] PARTICIPATION OF 5-HT3 RECEPTORS IN CHOLESTATIC PRURITUS
    SCHWORER, H
    HARTMANN, H
    RAMADORI, G
    HEPATOLOGY, 1993, 18 (04) : A302 - A302
  • [30] Trafficking of 5-HT3 and GABAA receptors (Review)
    Connolly, C. N.
    MOLECULAR MEMBRANE BIOLOGY, 2008, 25 (04) : 293 - 301